Celcuity (CELC) Share-based Compensation (2016 - 2025)
Celcuity (CELC) reported Share-based Compensation of $9.5 million for Q4 2025, up 308.47% on a YoY basis from $2.3 million in Q4 2024, and up 39.49% quarter-over-quarter from $6.8 million in Q3 2025.
Celcuity (CELC) Share-based Compensation (2016 - 2025) Analysis & Trends
Celcuity has reported Share-based Compensation for 10 years, with the latest figure at $9.5 million in Q4 2025.
- For the quarter ending Q4 2025, Share-based Compensation rose 308.47% year-over-year to $9.5 million; the trailing twelve-month figure through Dec 2025 stood at $21.4 million (up 206.0% YoY), and the FY2025 full-year result was $21.4 million, up 206.0% from the prior year.
- Share-based Compensation for Q4 2025 stood at $9.5 million, up from $6.8 million in the prior quarter.
- The five-year high for Share-based Compensation was $9.5 million in Q4 2025, with the low at $449098.0 in Q1 2021.
- Historically, Share-based Compensation has averaged $2.0 million across 5 years, with a median of $1.3 million in 2023.
- Annual changes were most pronounced in 2023 — Share-based Compensation decreased 15.96% — and 2025, when it surged 308.47%.
- Celcuity's Share-based Compensation stood at $920604.0 in 2021, then increased by 23.77% to $1.1 million in 2022, then advanced by 9.05% to $1.2 million in 2023, then jumped by 86.31% to $2.3 million in 2024, then surged by 308.47% to $9.5 million in 2025.
- The last three Share-based Compensation figures came in at $9.5 million (Q4 2025), $6.8 million (Q3 2025), and $2.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 26.47 Mn |
| 10 | Celcuity | 4.14 Bn | 3.42 Bn | - | 9.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.46 Mn |
| Dec 31, 2025 | 9.46 Mn |
| Sep 30, 2025 | 6.78 Mn |
| Sep 30, 2025 | 6.78 Mn |
| Jun 30, 2025 | 2.70 Mn |
| Jun 30, 2025 | 2.70 Mn |
| Mar 31, 2025 | 2.44 Mn |
| Mar 31, 2025 | 2.44 Mn |
| Dec 31, 2024 | 2.32 Mn |
| Dec 31, 2024 | 2.32 Mn |
| Sep 30, 2024 | 1.93 Mn |
| Sep 30, 2024 | 1.93 Mn |
| Jun 30, 2024 | 1.41 Mn |
| Jun 30, 2024 | 1.41 Mn |
| Mar 31, 2024 | 1.33 Mn |
| Mar 31, 2024 | 1.33 Mn |
| Dec 31, 2023 | 1.24 Mn |
| Dec 31, 2023 | 1.24 Mn |
| Sep 30, 2023 | 1.11 Mn |
| Sep 30, 2023 | 1.11 Mn |